Savara (SVRA) Accumulated Depreciation (2011 - 2025)
Savara (SVRA) posted quarterly Accumulated Depreciation of $2.3 million for Q4 2025, up 7.91% year-over-year from $2.2 million in Q4 2024, and up 7.91% quarter-over-quarter from $2.2 million in Q4 2024.
Savara (SVRA) Accumulated Depreciation (2011 - 2025) Analysis & Trends
Savara (SVRA) has reported Accumulated Depreciation for 15 consecutive years, with $2.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Depreciation rose 7.91% year-over-year to $2.3 million; the TTM figure through Dec 2025 stood at $2.3 million (up 7.91% YoY), while the FY2025 annual figure was $2.3 million, up 7.91% from the prior year.
- Accumulated Depreciation advanced to $2.3 million in Q4 2025 per SVRA's latest filing, from $2.2 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $2.3 million in Q4 2025 and bottomed at $1.9 million in Q4 2022.
- Historically, Accumulated Depreciation has averaged $2.1 million across 5 years, with a median of $2.1 million in 2021.
- Annual changes were most pronounced in 2022 — Accumulated Depreciation slipped 7.5% — and 2025, when it advanced 7.91%.
- Savara's Accumulated Depreciation stood at $2.1 million in 2021, then retreated by 7.5% to $1.9 million in 2022, then increased by 4.63% to $2.0 million in 2023, then advanced by 7.46% to $2.2 million in 2024, then advanced by 7.91% to $2.3 million in 2025.
- Business Quant data shows SVRA's Accumulated Depreciation at $2.3 million in Q4 2025, $2.2 million in Q4 2024, and $2.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.33 Mn |
| Dec 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | 2.01 Mn |
| Dec 31, 2022 | 1.92 Mn |
| Dec 31, 2021 | 2.08 Mn |
| Dec 31, 2020 | 1.97 Mn |
| Dec 31, 2019 | 1.67 Mn |
| Dec 31, 2018 | 1.37 Mn |
| Dec 31, 2017 | 851,000.00 |
| Dec 31, 2016 | 504,000.00 |
| Dec 31, 2015 | 339,000.00 |
| Dec 31, 2014 | 344,000.00 |
| Dec 31, 2013 | 262,000.00 |
| Dec 31, 2012 | 320,545.00 |
| Dec 31, 2011 | 274,187.00 |